Eli Lilly has requested Europe's drug regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said ...

Clinical academia is on a steep decline globally. In the UK, a 6% reduction in the number of clinical academics since 2012 has been reported, with the number of senior lecturer level researchers ...

Shares in pharmaceuticals giant Eli Lilly (LLY) were looking perkier today after it ramped up its battle to get a key ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

We recently published a list of Jim Cramer Says Trump’s Fed Chair Tussle Is Like “The Godfather” & Discusses These 10 Stocks.

Eli Lilly ( LLY 3.84%) and Novo Nordisk ( NVO 2.01%) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales ...

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...

Roche has said it will spend $50bn on manufacturing and research and development in the US, becoming the latest pharmaceutical company to promise greater investment in the face of potential tariffs on ...

US stocks plunged following Trump's comments, with the S&P 500 ( ^GSPC) closing Monday's session down 2.4%, the tech-focused Nasdaq ( ^IXIC) sliding 2.6% and the Dow Jones Industrial Average ( ^DJI) ...

Eli Lilly's robust sales for Mounjaro and Zepbound along with its positive outlook for 2025 also work in its favor. Click ...